cabergoline has been researched along with Body Weight in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Atabay, F; Ateş, Ç; Dilbaz, B; Ergani, SY | 1 |
| Abdullah, N; Aboelnaga, MM; Eladawy, EH; Elshafei, MM; Shaer, ME | 1 |
| Akdogan, A; Akman, L; Aktug, H; Erbas, O; Goker, EN; Sahin, G; Taskiran, D; Tavmergen, E | 1 |
| Arioz, DT; Dilek, H; Koken, T; Saylan, A; Saylan, F; Yilmazer, M | 1 |
| Barbosa, FR; Domingues, RC; dos Santos Silva, CM; Fontes, R; Gadelha, MR; Lima, GA; Warszawski, L | 1 |
| Hearn, CM; Renfree, MB; Shaw, G; Short, RV | 1 |
| Cancio, E; Cocchi, D; Dall'Ara, A; Devesa, J; Di Salle, E; Lima, L; Müller, EE | 1 |
7 other study(ies) available for cabergoline and Body Weight
| Article | Year |
|---|---|
Aflibercept suppresses ovarian hyperstimulation syndrome: an experimental study in rats.
Topics: Animals; Body Weight; Cabergoline; Female; Horses; Humans; Ovarian Hyperstimulation Syndrome; Pregnancy; Rats; Rats, Wistar; Vascular Endothelial Growth Factor A | 2023 |
Different Cabergoline Effect on Metabolic and Anthropometric Parameters in Female Prolactinoma Patients Versus Idiopathic Hyperprolactinemia Patients.
Topics: Adult; Anthropometry; Body Weight; Cabergoline; Dopamine Agonists; Female; Humans; Hyperprolactinemia; Insulin Resistance; Metabolome; Middle Aged; Prolactinoma; Treatment Outcome; Waist Circumference; Young Adult | 2019 |
Comparison of montelukast and cabergoline for prevention of ovarian hyperstimulation syndrome: in an experimental rat model.
Topics: Acetates; Animals; Ascitic Fluid; Body Weight; Cabergoline; Capillary Permeability; Chorionic Gonadotropin; Cyclopropanes; Dopamine Agonists; Ergolines; Female; Gonadotropins, Equine; Horses; Humans; Immunohistochemistry; Leukotriene Antagonists; Organ Size; Ovarian Hyperstimulation Syndrome; Ovary; Ovulation Induction; Quinolines; Rats; Rats, Wistar; Reproductive Control Agents; Sulfides; Vascular Endothelial Growth Factor A | 2015 |
Prevention of ovarian hyperstimulation syndrome in a rat model: efficacy comparison between cabergoline and meloxicam.
Topics: Analysis of Variance; Animals; Biopsy, Needle; Body Weight; Cabergoline; Chorionic Gonadotropin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Ergolines; Female; Immunohistochemistry; Injections, Intramuscular; Meloxicam; Organ Size; Ovarian Hyperstimulation Syndrome; Ovary; Ovulation Induction; Pregnancy; Pregnancy, Animal; Probability; Random Allocation; Rats; Rats, Wistar; Thiazines; Thiazoles; Vascular Endothelial Growth Factor A | 2010 |
BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists.
Topics: Adult; Aftercare; Aged; Blood Glucose; Body Composition; Body Mass Index; Body Weight; Bromocriptine; Cabergoline; Cholesterol, HDL; Cholesterol, LDL; Dopamine Agonists; Ergolines; Female; Humans; Insulin; Insulin Resistance; Leptin; Male; Metabolic Syndrome; Metabolome; Middle Aged; Obesity; Prevalence; Prolactinoma; Waist Circumference; Weight Gain; Young Adult | 2011 |
Effects of cabergoline on reproduction in three families of Australian marsupials.
Topics: Administration, Oral; Animals; Animals, Newborn; Body Weight; Cabergoline; Dopamine Agonists; Ergolines; Female; Injections, Intramuscular; Lactation; Macropodidae; Marsupialia; Pregnancy; Pregnancy, Animal; Prolactin; Reproduction | 1998 |
Inhibitory effect of cabergoline on the development of estrogen-induced prolactin-secreting adenomas of the pituitary.
Topics: Adenoma; Animals; Antineoplastic Agents; Body Weight; Bromocriptine; Cabergoline; DNA, Neoplasm; Ergolines; Estrogens; Female; Mitosis; Pituitary Neoplasms; Prolactin; Rats | 1988 |